← Scroll for more →
Amgen Inc (AMGN)
Biological Products, (No Diagnostic Substances)
Latest Price
$460.73
TTM P/E
28.63
Normalized P/E
38.11
TTM Div Yield
1.61%
Fwd Div Yield
1.61%
Book Value
21.66
P/B Ratio
21.27
Valuation metrics
adjust assumptions →EPS: $14.23
Book value / share: $16.07
Formula: √(22.5 × EPS × BVPS)
Graham Number
$71.73
84% downside
Norm. op. income: $9.1B (median of 7yr)
Tax rate: 12%
Discount rate: 10%
Growth assumption: zero (EPV is a no-growth value)
Earnings Power Value
$63.80
86% downside
Base FCF: $8.4B (median of recent 5yr)
Growth: -5%/yr (median YOY, capped at 25%)
Discount rate: 10%
Terminal growth: 3%
Projection horizon: 10 years
DCF Fair Value
$43.40
90% downside
EPS: $14.23
Target P/E: 37×
Formula: EPS × P/E
P/E Fair Value
$526.51
+17% upside
Institutional Ownership
85.4% held by institutions| Institution | Shares | Value | Ownership % | Change | Filing Date |
|---|---|---|---|---|---|
| BlackRock, Inc. | 49.36M | $17.87B | 9.13% | +2.26M | 2026-06-30 |
| Vanguard Capital Management LLC | 35.25M | $12.76B | 6.52% | +235.9K | 2026-06-30 |
| State Street Corp | 30.56M | $11.07B | 5.65% | +12.0K | 2026-06-30 |
| Capital World Investors | 29.08M | $10.53B | 5.38% | -213.0K | 2026-06-30 |
| Invesco Ltd. | 16.32M | $5.91B | 3.02% | +11.75M | 2026-06-30 |
| Geode Capital Management, LLC | 15.70M | $5.67B | 2.90% | +265.5K | 2026-06-30 |
| Charles Schwab Investment Management Inc | 15.03M | $5.44B | 2.78% | +2.26M | 2026-06-30 |
| Sixth Street Partners Management Company, L.P. | 15.03M | $5.44B | 2.78% | -- | 2026-06-30 |
| Vanguard Portfolio Management LLC | 14.85M | $5.38B | 2.75% | +232.2K | 2026-06-30 |
| Morgan Stanley | 13.65M | $4.94B | 2.53% | -2.18M | 2026-06-30 |